GIS Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
My Notes
NewNotes are coming soon
Gilead Sciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$74.35 |
52 Week High | US$84.73 |
52 Week Low | US$52.23 |
Beta | 0.43 |
1 Month Change | -8.45% |
3 Month Change | -7.90% |
1 Year Change | 29.17% |
3 Year Change | 19.92% |
5 Year Change | 12.82% |
Change since IPO | 446.99% |
Recent News & Updates
Recent updates
Shareholder Returns
GIS | DE Biotechs | DE Market | |
---|---|---|---|
7D | -2.6% | -2.4% | 3.4% |
1Y | 29.2% | 6.9% | -8.2% |
Return vs Industry: GIS exceeded the German Biotechs industry which returned 4.5% over the past year.
Return vs Market: GIS exceeded the German Market which returned -11.7% over the past year.
Price Volatility
GIS volatility | |
---|---|
GIS Average Weekly Movement | 3.1% |
Biotechs Industry Average Movement | 5.6% |
Market Average Movement | 5.2% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: GIS is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: GIS's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 14,400 | Dan O'Day | https://www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
Gilead Sciences, Inc. Fundamentals Summary
GIS fundamental statistics | |
---|---|
Market Cap | €96.56b |
Earnings (TTM) | €3.06b |
Revenue (TTM) | €24.87b |
30.6x
P/E Ratio3.8x
P/S RatioIs GIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GIS income statement (TTM) | |
---|---|
Revenue | US$27.14b |
Cost of Revenue | US$5.64b |
Gross Profit | US$21.50b |
Other Expenses | US$18.16b |
Earnings | US$3.33b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 2.66 |
Gross Margin | 79.22% |
Net Profit Margin | 12.29% |
Debt/Equity Ratio | 119.8% |
How did GIS perform over the long term?
See historical performance and comparison